View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
  2. Company News
May 14, 2018

Trial shows usefulness of chemotherapy in PVS treatment

A Boston Children’s Hospital trial in the US has found that adding chemotherapy to a treatment regimen such as catheterisation and surgery can detect abnormal cell growth and eventually help adolescents with pulmonary vein stenosis (PVS). 

A Boston Children’s Hospital trial in the US has found that adding chemotherapy to a treatment regimen such as catheterisation and surgery can detect abnormal cell growth and eventually help adolescents with pulmonary vein stenosis (PVS).

The trial initially included ten patients as a pilot and then expanded to enrol a total of 48 patients over a five-year period.

It was run by the Boston Children’s Hospital Pulmonary Vein Stenosis Programme with funding from Ansley’s Heart Endowment Fund, Christina Capozzi Memorial Foundation and TJ Reynolds Endowment Fund.

PVS is a rare disease where abnormal cells grow inside the veins responsible for carrying oxygen-rich blood from the lungs to the heart.

The disease usually affects young children by restricting blood flow through these vessels, and can completely seal them off if not treated.

The most severe form of PVS progresses very quickly and can lead to death within a matter of months after diagnosis.

“We’ve changed this disease from an acute killer to a chronic, manageable condition.”

Boston Children’s Hospital representative Christina Ireland said: “Through this approach, we’ve created the first-ever population of survivors who are living with severe PVS.

“We’ve changed this disease from an acute killer to a chronic, manageable condition.”

Boston Children’s cardiologist and researcher Kathy Jenkins was senior author on the paper that outlines the trial results. She said that the sooner patients were able to start chemotherapy, the better their chances of recovery.

Jenkins said: “By the 48th week of treatment, we were able to stabilise PVS progression and prevent further lung damage in 31% of the children we treated.

“At 72 weeks, 77% of patients treated per our protocol were still alive.”

Dana-Farber/Boston Children Cancer and Blood Disorders Center neuro-oncologist Mark Kieran and a team of collaborators, including Boston Children’s pathologist Sara Vargas, were also involved in the trial.

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU